Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A morphologic variant of uterine corpus leiomyoma characterized by zones of hemorrhagic infarction surrounded by hypercellular areas. It usually develops in women of childbearing years, particularly those that are pregnant, post-partum, or taking oral contraceptives.
Biomarker and diagnostic research for uterine corpus apoplectic leiomyoma has been reported in the published literature.
No clinical trials have been registered for uterine corpus apoplectic leiomyoma.
2 publications have been identified in PubMed for uterine corpus apoplectic leiomyoma. Research spans Diagnostic / Biomarker (50%) and Epidemiology / Natural History (50%).
Santoni C (2026). [PMID: 41707626](https://pubmed.ncbi.nlm.nih.gov/41707626/). *Spectrochim Acta A Mol Biomol Spectrosc*. [Diagnostic / Biomarker]
He S (2024). [PMID: 39217279](https://pubmed.ncbi.nlm.nih.gov/39217279/). *BMC Womens Health*. [Epidemiology / Natural History]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 11:58 PM UTC